Raquel de Andrés

5PUBLICATIONS
70CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 26, 2026
Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

|Dec 12, 2025
Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.

Miguel Martín, Ángel L Guerrero-Zotano, María E Pérez-López

|Sep 16, 2024
High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer.

Miguel Quintela-Fandino, Begoña Bermejo, Esther Zamora

|Apr 01, 2024
First-line therapy with palbociclib in patients with advanced HR+/HER2- breast cancer: The real-life study PALBOSPAIN.

N Martínez-Jañez, M Bellet Ezquerra, L M Manso Sanchez

|Jul 12, 2019
Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report.

Raquel Andrés, Sebastian Menao, María Arruebo

Pageof 1

Frequent Collaborators

4 joint publications

Noelia Martínez-Jañez

3 joint publications

Emilio Alba

2 joint publications

Luis Manso

2 joint publications

Angel L Guerrero-Zotano